PPARG and malignant colon neoplasm: Antitumor activity of PPARγ agonists has been shown in tumor cells derived from liposarcoma, colon cancer, breast cancer, leukemia, gastric cancer, nonsmall cell lung cancer, and prostate cancer [19–31].